You have free access to this content

Cancer

Cover image for Vol. 118 Issue 5

1 March 2012

Volume 118, Issue 5

Pages 1175–1470

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
      Determining the optimal dose and schedule of sunitinib : Some Answers, More Questions (pages 1178–1180)

      Cristina Suarez and Brian I. Rini

      Version of Record online: 6 SEP 2011 | DOI: 10.1002/cncr.26426

      Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors. In this issue, Barrios et al present a study in which 120 treatment-naive patients with metastatic RCC were enrolled in a single-arm, open-label, phase 2 trial of continuous once-daily sunitinib. This study and other data provide insight into optimal dosing of sunitinib in metastatic RCC.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have full text access to this OnlineOpen article
      Suboptimal responses in chronic myeloid leukemia : Implications and management strategies (pages 1181–1191)

      Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes and Hagop Kantarjian

      Version of Record online: 28 OCT 2011 | DOI: 10.1002/cncr.26391

      • original image

      Long-term outcomes for suboptimal responders to imatinib therapy may not be as favorable as those for optimally responding patients. Identification of suboptimal responders or patients failing treatment using hematologic, cytogenetic, and molecular techniques allows physicians to alter therapy earlier in the treatment course to improve long-term outcomes.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. Disease Site

      Breast Disease
      You have free access to this content
      Final 5-year results of Z-FAST trial : Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole (pages 1192–1201)

      Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson and Edith A. Perez

      Version of Record online: 10 OCT 2011 | DOI: 10.1002/cncr.26313

      • original image
      • original image
      • original image

      Upfront zoledronic acid appears to significantly increase bone mineral density in postmenopausal women with early breast cancer receiving letrozole for 5 years versus delayed zoledronic acid administration. Long-term coadministration of letrozole and zoledronic acid is well tolerated.

    2. You have free access to this content
      Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer (pages 1202–1211)

      Soley Bayraktar, Leonel F. Hernadez-Aya, Xiudong Lei, Funda Meric-Bernstam, Jennifer K. Litton, Limin Hsu, Gabriel N. Hortobagyi and Ana M. Gonzalez-Angulo

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26439

      • original image

      Concurrent use of metformin with adjuvant chemotherapy does not appear to significantly impact survival outcomes in diabetic patients with triple receptor-negative breast cancer. However, compared with the metformin group, patients who are not treated with metformin and nondiabetic patients tend to have a higher risk of distant metastases.

    3. You have free access to this content
      Limited evidence of human papillomavirus on breast tissue using molecular in situ methods (pages 1212–1220)

      Kimberly Baltzell, Gertrude C. Buehring, Savitri Krishnamurthy, Henry Kuerer, Hua Min Shen and Jennette D. Sison

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26389

      • original image
      • original image

      The use of in situ molecular methods of viral detection to reassess the frequency of human papillomavirus (HPV) in malignant breast tissue produces limited evidence of HPV in breast tissue of women with breast cancer. However, given the presence of HPV in 8.6% of breast cancer specimens in this study, further investigation in women with no history of breast cancer is warranted to test causal association.

      Corrected by:

      Erratum: Erratum: Limited evidence of human papillomavirus on breast tissue using molecular in situ methods

      Vol. 118, Issue 9, 2561, Version of Record online: 6 SEP 2011

    4. You have free access to this content
      Effect of CYP2D6 polymorphisms on breast cancer recurrence (pages 1221–1227)

      Phuong K. Morrow, Ruben Serna, Kristine Broglio, Lajos Pusztai, D. Michelle Nikoloff, Grantland R. Hillman, Marcel Fontecha, Rui Li, Laura Michaud, Gabriel Hortobagyi and Ana M. Gonzalez-Angulo

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26407

      The authors performed a case-control study to determine the effect of cytochrome P450 2D6 (CYP2D6) genotype on risk of recurrence in early breast cancer patients who were receiving tamoxifen. The study found that after adjustment for stage, CYP2D6 inhibitors, and follow-up time, CYP2D6 genotype was not associated with a significant effect on disease recurrence in breast cancer patients who were taking tamoxifen.

    5. Endocrine Disease
      You have free access to this content
      Family history of cancer and risk of sporadic differentiated thyroid carcinoma (pages 1228–1235)

      Li Xu, Guojun Li, Qingyi Wei, Adel K. El-Naggar and Erich M. Sturgis

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26398

      Family history of thyroid cancer in first-degree relatives, particularly in siblings, is associated with an increased risk of sporadic differentiated and papillary thyroid carcinoma.

    6. Gastrointestinal Disease
      You have free access to this content
      Exposure to bisphosphonates and risk of colorectal cancer : A population-based nested case-control study (pages 1236–1243)

      Harminder Singh, Zoann Nugent, Alain Demers, Salaheddin Mahmud and Charles Bernstein

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26395

      The results from this study suggest that exposure to bisphosphonates may reduce the risk of presenting with colorectal cancer. Among the individual bisphosphonate agents, the benefit from risendronic acid may be the greatest.

    7. You have free access to this content
      Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers (pages 1244–1251)

      Sunil Amin, Russell B. McBride, Jennie K. Kline, Elana B. Mitchel, Aimee L. Lucas, Alfred I. Neugut and Harold Frucht

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26414

      Understanding metachronous cancer associations can modify pancreas cancer risk. Primary malignancies associated with certain environmental and genetic risk factors are associated with the development of pancreatic adenocarcinoma later in life.

    8. Genitourinary Disease
      You have free access to this content
      Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma (pages 1252–1259)

      Carlos H. Barrios, David Hernandez-Barajas, Michael P. Brown, Se-Hoon Lee, Luis Fein, Jin-Hwang Liu, Subramanian Hariharan, Bridget A. Martell, Jinyu Yuan, Akintunde Bello, Zhixiao Wang, Rajiv Mundayat and Sun-Young Rha

      Version of Record online: 6 SEP 2011 | DOI: 10.1002/cncr.26440

      • original image
      • original image

      One hundred nineteen treatment-naive patients with metastatic renal cell carcinoma (RCC) received once-daily dosing of sunitinib 37.5 mg. Continuous dosing with sunitinib was active with a manageable safety profile as first-line metastatic RCC therapy, making this a feasible alternative dosing regimen.

    9. You have free access to this content
      Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States (pages 1260–1267)

      Sandip M. Prasad, Xiangmei Gu, Stuart R. Lipsitz, Paul L. Nguyen and Jim C. Hu

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26416

      • original image
      • original image

      Radiographic staging in men with incident prostate cancer is overused in men with low-risk and intermediate-risk disease and underused in men with high-risk disease. This may have significant financial and treatment-related consequences.

    10. You have free access to this content
      Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma (pages 1268–1275)

      Sarah Minner, Dorothea Rump, Pierre Tennstedt, Ronald Simon, Eike Burandt, Luigi Terracciano, Holger Moch, Waldemar Wilczak, Carsten Bokemeyer, Margit Fisch, Guido Sauter and Christian Eichelberg

      Version of Record online: 23 AUG 2011 | DOI: 10.1002/cncr.26436

      • original image

      Increased epidermal growth factor receptor (EGFR) expression, which, in some patients, may be caused by EGFR copy number changes, occurs in a fraction of patients who have renal cell carcinoma with an unfavorable histologic phenotype. High polysomy occurs in about 5% of renal cell carcinomas, but EGFR gene mutations (the strongest predictor of a possible response to tyrosine kinase inhibitors) are not observed.

    11. Head and Neck Disease
      You have free access to this content
      Impact of radiotherapy on laryngeal cancer survival : A Population-Based Study of 13,808 US Patients (pages 1276–1287)

      Hong Zhang, Lois B. Travis, Rui Chen, Ollivier Hyrien, Michael T. Milano, Shawn D. Newlands and Yuhchyau Chen

      Version of Record online: 19 JUL 2011 | DOI: 10.1002/cncr.26357

      • original image
      • original image

      The increasing use of radiation over the past 2 decades has had no adverse impact on laryngeal cancer survival. Black race and residence in low-income counties are associated with a significantly lower frequency of radiotherapy administration.

    12. You have free access to this content
      Developmental transcription factor EN1—a novel biomarker in human salivary gland adenoid cystic carcinoma (pages 1288–1292)

      Diana Bell, Achim Bell, Dianna Roberts, Randal S. Weber and Adel K. El-Naggar

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26412

      • original image
      • original image

      The authors validate the developmental transcription factor engrailed homeobox 1 (EN1) as a potential biomarker in a large cohort of patients with salivary adenoid cystic carcinoma (ACC). Immunohistochemical analysis of EN1 in biopsy specimens obtained for diagnostic purposes and/or surgically resected material reveals that EN1 is a biologic predictor of poor prognosis in patients with salivary ACC.

    13. Lung Disease
      You have free access to this content
      Expression of focal adhesion kinase in small-cell lung carcinoma (pages 1293–1301)

      Sebahat Ocak, Heidi Chen, Clay Callison, Adriana L. Gonzalez and Pierre P. Massion

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26382

      • original image
      • original image

      Total focal adhesion kinase is strongly expressed in small-cell lung carcinoma but is not associated with disease stage, response to therapy, recurrence/progression-free survival, and overall survival.

    14. Neuro-Oncology
      You have free access to this content
      Bevacizumab and daily temozolomide for recurrent glioblastoma (pages 1302–1312)

      Annick Desjardins, David A. Reardon, April Coan, Jennifer Marcello, James E. Herndon II, Leighann Bailey, Katherine B. Peters, Henry S. Friedman and James J. Vredenburgh

      Version of Record online: 26 JUL 2011 | DOI: 10.1002/cncr.26381

      • original image
      • original image
      • original image

      Bevacizumab and daily temozolomide in monotherapy appear to have clinically meaningful activity in recurrent glioblastoma. In this trial, the authors demonstrate that bevacizumab and daily temozolomide in combination therapy have some activity and are well tolerated.

    15. You have free access to this content
      Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs) (pages 1313–1322)

      Nicolas R. Smoll

      Version of Record online: 11 AUG 2011 | DOI: 10.1002/cncr.26387

      • original image
      • original image
      • original image
      • original image

      Data from this study provide guidance in the development of follow-up schedules after a diagnosis of a medulloblastoma or primitive neuroectodermal tumor. Differences in survival between children and adults with these tumors emerge only 4 years after diagnosis, and adults fare worse.

    16. You have free access to this content
      Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer (pages 1323–1333)

      Zhiyuan Xu, Nicholas F. Marko, Lilyana Angelov, Gene H. Barnett, Samuel T. Chao, Michael A. Vogelbaum, John H. Suh and Robert J. Weil

      Version of Record online: 25 AUG 2011 | DOI: 10.1002/cncr.26314

      • original image

      Stereotactic radiosurgery (SRS) is one of several potential treatment options that may be effective for patients with brain metastasis from breast cancer, and markers that correlate with the degree of individual patient response to SRS and with overall outcome are of value to clinicians deciding upon management strategies for these patients. We demonstrated that radiographic evidence of necrosis at the time of stereotactic radiosurgery is associated with diminished efficacy of SRS therapy and is a negative prognostic marker.

    17. Discipline

      Disparities Research
      You have free access to this content
      Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women (pages 1334–1344)

      Lori A. Field, Brad Love, Brenda Deyarmin, Jeffrey A. Hooke, Craig D. Shriver and Rachel E. Ellsworth

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26405

      • original image
      • original image
      • original image

      Molecular analysis of invasive breast tumors as well as nonmalignant breast tissues reveal differences in gene expression between African American and Caucasian women. These differences in expression of genes involve immunity, cell growth, and differentiation, and invasion and metastasis may contribute to aggressive breast cancer in African American women.

    18. You have free access to this content
      Does a standard measure of self-reported physical disability correlate with clinician perception of impairment related to cancer screening? (pages 1345–1352)

      David I. Buckley, Melinda M. Davis and Elena M. Andresen

      Version of Record online: 23 AUG 2011 | DOI: 10.1002/cncr.26393

      Patient self-reported limitations in activities of daily living and instrumental activities of daily living do not correlate well with clinician perception of impairment related to cancer screening. A disability measurement instrument designed to assess factors relevant for cancer screening may be useful for identifying and accommodating patients who are at increased risk of not receiving cancer control services.

    19. Epidemiology
      You have free access to this content
      The impact of type 2 diabetes mellitus on cancer-specific survival : A follow-up study in sweden (pages 1353–1361)

      Xiangdong Liu, Jianguang Ji, Kristina Sundquist, Jan Sundquist and Kari Hemminki

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26420

      • original image

      The authors study nationwide, population-based Swedish registries and compare cause-specific survival between cancer patients with and without type 2 diabetes mellitus (T2DM). The results indicate that patients with T2DM who are diagnosed with subsequent cancer are at an increased risk of cause-specific mortality compared with patients with cancer who do not have T2DM.

    20. You have free access to this content
      Novel germline PALB2 truncating mutations in African American breast cancer patients (pages 1362–1370)

      Yonglan Zheng, Jing Zhang, Qun Niu, Dezheng Huo and Olufunmilayo I. Olopade

      Version of Record online: 26 AUG 2011 | DOI: 10.1002/cncr.26388

      • original image

      Three novel, monoallelic, truncating mutations of the partner and localizer of breast cancer 2 gene PALB2 are detected in African American women with both familial and nonfamilial breast cancer. Although their clinical significance is undetermined, rare PALB2 mutations account for a small but substantial proportion of breast cancers.

    21. You have free access to this content
      Peak and decline in cancer incidence, mortality, and prevalence at old ages (pages 1371–1386)

      Charles Harding, Francesco Pompei and Richard Wilson

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26376

      • original image
      • original image

      Studying common cancer types in the US Surveillance, Epidemiology, and End Results 9 registries, the authors find that age-specific incidence, mortality, and prevalence normally peak between ages 75 and 95 years and, when the results have statistical power, usually drop abruptly afterward.

    22. You have free access to this content
      Sarcomas in TP53 germline mutation carriers : A review of the IARC TP53 database (pages 1387–1396)

      Simona Ognjanovic, Magali Olivier, Tracy L. Bergemann and Pierre Hainaut

      Version of Record online: 11 AUG 2011 | DOI: 10.1002/cncr.26390

      • original image
      • original image

      The authors use the International Agency for Research on Cancer tumor protein p53 gene (TP53) database to analyze the types, age at onset, and mutation patterns of sarcoma in TP53 mutation carriers. These data are compared with sarcoma types in the general population of Caucasians using the National Cancer Institute's Surveillance, Epidemiology, and End Results Program data to improve the characterization of sarcomas occurring in carriers.

    23. You have free access to this content
      Racial variation in tumor stage at diagnosis among Department of Defense beneficiaries (pages 1397–1403)

      Lindsey Enewold, Jing Zhou, Katherine A. McGlynn, Susan S. Devesa, Craig D. Shriver, John F. Potter, Shelia H. Zahm and Kangmin Zhu

      Version of Record online: 11 AUG 2011 | DOI: 10.1002/cncr.26208

      Racial disparities in tumor stage at diagnosis were observed particularly among older nonactive duty beneficiaries in the Department of Defense Health System, which provides all racial groups with equal access to medical care.

    24. Outcomes Research
      You have free access to this content
      Improved outcomes associated with higher surgery rates for older patients with early stage nonsmall cell lung cancer (pages 1404–1411)

      Stacy W. Gray, Mary Beth Landrum, Elizabeth B. Lamont, Barbara J. McNeil, Michael T. Jaklitsch and Nancy L. Keating

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26363

      Uncertainty exists about the benefits versus the risks of surgery for early stage nonsmall cell lung cancer in older patients. The authors of this report used a geographic analysis to address bias and observed that higher rates of surgery for stage I/II nonsmall cell lung cancer were associated with improved survival, even when older patients and sicker patients underwent resection.

    25. You have free access to this content
      Quality of care in patients with bladder cancer : A case report? (pages 1412–1421)

      Karim Chamie, Christopher S. Saigal, Julie Lai, Jan M. Hanley, Claude M. Setodji, Badrinath R. Konety, Mark S. Litwin and the Urologic Diseases in America Project

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26402

      Although there is level I evidence demonstrating the superiority of intravesical therapy in patients with bladder cancer, surveillance strategies are primarily founded on expert opinion. The authors examined compliance with surveillance and treatment strategies and the pursuant impact on survival in patients with high-grade disease.

    26. You have free access to this content
      Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center (pages 1422–1428)

      Ignacio Garrido-Laguna, Filip Janku, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen and Razelle Kurzrock

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26413

      • original image
      • original image

      This work demonstrates that the Royal Marsden Hospital prognostic score is independent of the center, patient population, and treating physician. In addition, a subpopulation of patients is identified (with a Royal Marsden Hospital prognostic score of 3) in which the median survival is only 4 weeks. This subgroup may need to be excluded from phase 1 trials; or, alternatively, washout periods may need to be minimized for these patients

    27. You have free access to this content
      The impact of July hospital admission on outcome after surgery for spinal metastases at academic medical centers in the United States, 2005 to 2008 (pages 1429–1438)

      Hormuzdiyar H. Dasenbrock, Michelle J. Clarke, Richard E. Thompson, Ziya L. Gokaslan and Ali Bydon

      Version of Record online: 25 AUG 2011 | DOI: 10.1002/cncr.26347

      • original image
      • original image

      In this nationwide study, 2920 patients who underwent surgery for spinal metastases at academic medical centers were examined. Patients admitted in July had significantly higher adjusted odds of in-hospital death and development of an intraoperative complication compared with those admitted between August and June.

    28. Pediatric Oncology
      You have free access to this content
      Educational achievement in Swiss childhood cancer survivors compared with the general population (pages 1439–1449)

      Claudia E. Kuehni, Marie-Pierre F. Strippoli, Corina S. Rueegg, Cornelia E. Rebholz, Eva Bergstraesser, Michael Grotzer, Nicolas X. von der Weid, Gisela Michel and for the Swiss Pediatric Oncology Group (SPOG)

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26418

      • original image
      • original image
      • original image

      Childhood cancer survivors encounter problems during schooling and complete professional education with some delay. However, with the exception of patients who have brain tumors and those who have had a relapse, the final educational achievement in survivors of childhood cancer is comparable to that in the general population.

    29. You have free access to this content
      Pulmonary function after whole lung irradiation in pediatric patients with solid malignancies (pages 1450–1456)

      Megan S. Motosue, Liang Zhu, Kumar Srivastava, Dennis C. Stokes, Melissa M. Hudson, Valerie McPherson, Saumini Srinivasan, Matthew J. Krasin, Daniel M. Green, Sheri L. Spunt and Hiroto Inaba

      Version of Record online: 28 JUL 2011 | DOI: 10.1002/cncr.26371

      • original image
      • original image

      This retrospective study of longitudinal changes in pulmonary function tests (PFTs) of survivors of pediatric malignant solid tumors who were treated with whole lung irradiation shows frequent abnormalities in PFT parameters, especially in lung volumes, which deteriorated over time. These findings suggest that long-term, continual follow-up of pulmonary function and symptoms, timely intervention, and patient education are important.

    30. Quality of Life
      You have free access to this content
      International field testing of the reliability and validity of the EORTC QLQ-BM22 module to assess health-related quality of life in patients with bone metastases (pages 1457–1465)

      Edward Chow, Janet Nguyen, Liying Zhang, Ling-Ming Tseng, Ming-Feng Hou, Alysa Fairchild, Vassilios Vassiliou, Reynaldo Jesus-Garcia, Mohamed A. Alm El-Din, Aswin Kumar, Fabien Forges, Wei-Chu Chie, Andrew Bottomley and On behalf of the European Organization for Research Treatment of Cancer Quality of Life Group

      Version of Record online: 11 AUG 2011 | DOI: 10.1002/cncr.26410

      Results of the current study have confirmed the validity, reliability, cross-cultural applicability, and sensitivity of the 22-item European Organization for Research and Treatment of Cancer (EORTC) QLQ-BM22 module. It is therefore recommended that the QLQ-BM22 be used in addition to the QLQ-C30 in clinical trials to assess health-related quality of life in patients with bone metastases.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
      Reply to cancer survivorship and sexual orientation (page 1469)

      Ulrike Boehmer, Xiaopeng Miao and Al Ozonoff

      Version of Record online: 5 AUG 2011 | DOI: 10.1002/cncr.26408

  6. Errata

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Errata
    1. You have free access to this content
    2. You have free access to this content

SEARCH

SEARCH BY CITATION